PCN41 DRUG COST CONSIDERATIONS FOR ERYTHROPOIETIC STIMULATING THERAPIES (ESTS) AGENTS IN PATIENTS INITIATED AT FDA-APPROVED DOSING- RESULTS FROM PRACTICE PATTERNS IN A PROSPECTIVE OBSERVATIONAL STUDY

May 1, 2007, 00:00 AM
10.1016/S1098-3015(10)68951-6
https://www.valueinhealthjournal.com/article/S1098-3015(10)68951-6/fulltext
Section Title :
Section Order : 134
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)68951-6&doi=10.1016/S1098-3015(10)68951-6
HEOR Topics :
Tags :
Regions :